ASCO25: J&J’s trispecific antibody shows 100% response in Phase I multiple myeloma study

First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma space.

Jun 5, 2025 - 06:00

ASCO25: J&J’s trispecific antibody shows 100% response in Phase I multiple myeloma study

First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma space.

Read the original article

Tags:

Previous Article

EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma

Sanofi Makes $9.5 Billion Bet on Rare Disease Drugmaker

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

The U.S. hasn’t seen syphilis numbers this high since 1950. Other STD rates are down or flat

The U.S. hasn’t seen syphilis numbers this high since 1...

Jan 30, 2024

STAT+: KRAS, the ideal cancer drug target that became ‘undruggable,’ takes on a new glow

STAT+: KRAS, the ideal cancer drug target that became ‘...

Aug 31, 2023

Unmatched quality in pharmaceutical logistics: Why it matters

Unmatched quality in pharmaceutical logistics: Why it m...

Mar 27, 2025